Pharsight

Fresenius Kabi Usa patents expiration

1. Acetaminophen patents expiration

ACETAMINOPHEN's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8741959 FRESENIUS KABI USA Paracetamol for parenteral administration
Apr, 2030

(5 years from now)

Drugs and Companies using ACETAMINOPHEN ingredient

Market Authorisation Date: 28 October, 2015

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

ACETAMINOPHEN family patents

Family Patents

2. Bortezomib patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8962572 FRESENIUS KABI USA Bortezomib formulations
Nov, 2032

(8 years from now)

Drugs and Companies using BORTEZOMIB ingredient

Market Authorisation Date: 06 November, 2017

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

BORTEZOMIB family patents

Family Patents

3. Caspofungin Acetate patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9636407 FRESENIUS KABI USA Caspofungin acetate formulations
Dec, 2032

(8 years from now)

Drugs and Companies using CASPOFUNGIN ACETATE ingredient

Market Authorisation Date: 30 December, 2016

Treatment: NA

Dosage: POWDER;INTRAVENOUS

More Information on Dosage

CASPOFUNGIN ACETATE family patents

Family Patents

4. Dilaudid patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6589960 FRESENIUS KABI USA Hydromorphone and hydrocodone compositions and methods for their synthesis
Nov, 2020

(3 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9731082 FRESENIUS KABI USA Drug container
Apr, 2032

(8 years from now)

US9248229 FRESENIUS KABI USA Packaging system for oxygen-sensitive drugs
Mar, 2034

(9 years from now)

Drugs and Companies using HYDROMORPHONE HYDROCHLORIDE ingredient

Market Authorisation Date: 16 January, 2020

Treatment: NA

Dosage: INJECTABLE;INJECTION

How can I launch a generic of DILAUDID before it's drug patent expiration?
More Information on Dosage

DILAUDID family patents

Family Patents

5. Dilaudid-hp patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6589960 FRESENIUS KABI USA Hydromorphone and hydrocodone compositions and methods for their synthesis
Nov, 2020

(3 years ago)

US9731082 FRESENIUS KABI USA Drug container
Apr, 2032

(8 years from now)

US9248229 FRESENIUS KABI USA Packaging system for oxygen-sensitive drugs
Mar, 2034

(9 years from now)

Drugs and Companies using HYDROMORPHONE HYDROCHLORIDE ingredient

Market Authorisation Date: 16 January, 2020

Treatment: NA

Dosage: INJECTABLE;INJECTION

How can I launch a generic of DILAUDID-HP before it's drug patent expiration?
More Information on Dosage

DILAUDID-HP family patents

Family Patents

6. Diprivan patents expiration

DIPRIVAN Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8476010 FRESENIUS KABI USA Propofol formulations with non-reactive container closures
Dec, 2024

(7 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5908869 FRESENIUS KABI USA Propofol compositions containing edetate
Mar, 2015

(9 years ago)

US5714520 FRESENIUS KABI USA Propofol compostion containing edetate
Mar, 2015

(9 years ago)

US5731355 FRESENIUS KABI USA Pharmaceutical compositions of propofol and edetate
Mar, 2015

(9 years ago)

US5731356 FRESENIUS KABI USA Pharmaceutical compositions of propofol and edetate
Mar, 2015

(9 years ago)

US5714520

(Pediatric)

FRESENIUS KABI USA Propofol compostion containing edetate
Sep, 2015

(8 years ago)

US5731356

(Pediatric)

FRESENIUS KABI USA Pharmaceutical compositions of propofol and edetate
Sep, 2015

(8 years ago)

US5908869

(Pediatric)

FRESENIUS KABI USA Propofol compositions containing edetate
Sep, 2015

(8 years ago)

US5731355

(Pediatric)

FRESENIUS KABI USA Pharmaceutical compositions of propofol and edetate
Sep, 2015

(8 years ago)

US8476010

(Pediatric)

FRESENIUS KABI USA Propofol formulations with non-reactive container closures
Jun, 2025

(1 year, 1 month from now)

Drugs and Companies using PROPOFOL ingredient

Market Authorisation Date: 02 October, 1989

Treatment: Method of improving the time for administration or the time between changes of giving sets for the drug product; Method of producing anesthesia; Method for limiting the potential for microbial growth ...

Dosage: INJECTABLE;INJECTION

How can I launch a generic of DIPRIVAN before it's drug patent expiration?
More Information on Dosage

DIPRIVAN family patents

Family Patents

7. Fulvestrant patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10188663 FRESENIUS KABI USA Fulvestrant formulations
Feb, 2034

(9 years from now)

US9833459 FRESENIUS KABI USA Fulvestrant formulations
Feb, 2034

(9 years from now)

US9271990 FRESENIUS KABI USA Fulvestrant formulations
May, 2034

(10 years from now)

Drugs and Companies using FULVESTRANT ingredient

Market Authorisation Date: 20 May, 2019

Treatment: Treatment of hormone receptor positive advanced breast cancer in postmenopausal women

Dosage: SOLUTION;INTRAMUSCULAR

More Information on Dosage

FULVESTRANT family patents

Family Patents

8. Levothyroxine Sodium patents expiration

LEVOTHYROXINE SODIUM Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9168238 FRESENIUS KABI USA Levothyroxine formulations
Aug, 2032

(8 years from now)

US9168239 FRESENIUS KABI USA Levothyroxine formulations
Aug, 2032

(8 years from now)

US9006289 FRESENIUS KABI USA Levothyroxine formulations
Oct, 2032

(8 years from now)

US9782376 FRESENIUS KABI USA Levothyroxine liquid formulations
Dec, 2036

(12 years from now)

US11135190 FRESENIUS KABI USA Levothyroxine liquid formulations
Dec, 2036

(12 years from now)

US10398669 FRESENIUS KABI USA Levothyroxine liquid formulations
Dec, 2036

(12 years from now)

Drugs and Companies using LEVOTHYROXINE SODIUM ingredient

Market Authorisation Date: 24 June, 2011

Treatment: NA

Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS

How can I launch a generic of LEVOTHYROXINE SODIUM before it's drug patent expiration?
More Information on Dosage

LEVOTHYROXINE SODIUM family patents

Family Patents

9. Morphine Sulfate patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9248229 FRESENIUS KABI USA Packaging system for oxygen-sensitive drugs
Mar, 2034

(9 years from now)

US9072781 FRESENIUS KABI USA Morphine formulations
Mar, 2034

(9 years from now)

US9192608 FRESENIUS KABI USA Morphine formulations
Mar, 2034

(9 years from now)

Drugs and Companies using MORPHINE SULFATE ingredient

Market Authorisation Date: 30 October, 2013

Treatment: Treatment of pain

Dosage: SOLUTION;INTRAMUSCULAR, INTRAVENOUS

More Information on Dosage

MORPHINE SULFATE family patents

Family Patents

10. Naropin patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5834489 FRESENIUS KABI USA Methods and compositions for the treatment of pain utilizing ropivacaine
May, 2014

(9 years ago)

US5670524 FRESENIUS KABI USA Methods and compositions for the treatment of pain utilizing ropivacaine
Sep, 2014

(9 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8118802 FRESENIUS KABI USA Connector for packaging containing medical fluids and packaging for medical fluids
May, 2023

(11 months ago)

US8162915 FRESENIUS KABI USA Connector for packings containing medical liquids, and corresponding packing for medical liquids
May, 2024

(a month from now)

US7828787 FRESENIUS KABI USA Connector for packaging containing medical fluids and packaging for medical fluids
Oct, 2025

(1 year, 5 months from now)

US7857802 FRESENIUS KABI USA Connector for medical liquid-containing packages and medical liquid-containing packages
Nov, 2026

(2 years from now)

Drugs and Companies using ROPIVACAINE HYDROCHLORIDE ingredient

Market Authorisation Date: 04 January, 2011

Treatment: Method of treating pain using a pharmaceutically acceptable salt of ropivacaine and administering a composition containing less than 0.5% by weight of ropivacaine; Method of treating pain using a phar...

Dosage: SOLUTION;INJECTION

How can I launch a generic of NAROPIN before it's drug patent expiration?
More Information on Dosage

NAROPIN family patents

Family Patents

11. Omegaven patents expiration

OMEGAVEN Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10350186 FRESENIUS KABI USA Treatment and prevention of liver disease associated with parenteral nutrition (PN)
Nov, 2024

(6 months from now)

US9566260 FRESENIUS KABI USA Treatment and prevention of liver disease associated with parenteral nutrition (PN)
Jul, 2025

(1 year, 2 months from now)

US9629821 FRESENIUS KABI USA Treatment and prevention of liver disease associated with parenteral nutrition (PN)
Jul, 2025

(1 year, 2 months from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-202) Jul 27, 2025
New Chemical Entity Exclusivity(NCE) Jul 27, 2023

Drugs and Companies using FISH OIL TRIGLYCERIDES ingredient

NCE-1 date: 27 July, 2022

Market Authorisation Date: 27 July, 2018

Treatment: Treatment of parenteral nutrition-associated cholestasis in patients under the age of 12; Treatment of liver disease through nutrition for patients under the age of 12; Use for patients with parentera...

Dosage: EMULSION;INTRAVENOUS

More Information on Dosage

OMEGAVEN family patents

Family Patents